^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    abiraterone acetate

    i
    Other names: CB 7630, JNJ-212082, CB-7630, CB7630, BR9004
    Company:
    Generic mfg.
    Drug class:
    CYP17A1 inhibitor
    Related drugs:
    4d
    Study on the efficacy and safety of abiraterone acetate tablets (II) + ADT + chemotherapy in first-line treatment of mCRPC (ChiCTR2500111854)
    P4, N=36, Not yet recruiting, Affiliated Hospital of Guizhou Medical University; Affiliated Hospital of Guizhou Medical University
    New P4 trial
    |
    docetaxel • abiraterone acetate • prednisone
    7d
    Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (177Lu)Vipivotide Tetraxetan, and Abiraterone. (PubMed, J Clin Med)
    We conclude that the optimal use of PARP inhibitors, PSMA-targeted RLT, and ARPIs requires a personalized strategy guided by molecular profiling, functional imaging, prior treatment exposure, and safety considerations. This clinically focused overview aims to support evidence-based decision-making in an increasingly complex treatment landscape.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • AR (Androgen receptor) • HRD (Homologous Recombination Deficiency)
    |
    FOLH1 positive
    |
    Lynparza (olaparib) • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    7d
    c15-164: AASUR in High Risk Prostate Cancer (clinicaltrials.gov)
    P2, N=64, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Jan 2026 | Trial primary completion date: May 2026 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    abiraterone acetate • apalutamide • leuprolide acetate for depot suspension
    8d
    Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=31, Completed, Montefiore Medical Center | Active, not recruiting --> Completed
    Trial completion • First-in-human
    |
    abiraterone acetate • prednisone
    9d
    Evolution of AR and non-AR alterations in circulating tumor DNA of metastatic prostate cancer patients treated in the phase 3 Alliance A031201 trial. (PubMed, Clin Cancer Res)
    AR alterations in ctDNA accumulate at progression in mCRPC patients treated with ARPIs, especially in those with initially durable responses. These findings support the use of liquid biopsy to serially track resistance mechanisms and inform precision therapy in advanced prostate cancer.
    P3 data • Journal • Circulating tumor DNA
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • FANCA (FA Complementation Group A) • POLD1 (DNA Polymerase Delta 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • ZNRF3 (Zinc And Ring Finger 3)
    |
    Xtandi (enzalutamide) • abiraterone acetate
    16d
    Twelve mutations, three trials, and five different labels: PARP inhibitors regulatory inconsistencies in prostate cancers. (PubMed, EClinicalMedicine)
    Of all trials, only MAGNITUDE, evaluating niraparib and abiraterone, led to aligned conclusions from both the EMA and FDA, as its design effectively identified the subgroup most likely to benefit. Currently, there is a need for harmonisation in biomarker-driven trial designs and the definition of homologous recombination repair deficiency (HRD). Access to biomarker and clinical data from all PARP-inhibitor trials would allow researchers to clarify the impact of different HRR mutations on outcomes.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Zejula (niraparib) • abiraterone acetate
    16d
    PARP Inhibitor Olaparib and Its Combination Therapy in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-analysis. (PubMed, Eur Urol Open Sci)
    However, for BRCA-mutated mCRPC, olaparib combined with abiraterone improved PFS (HR = 0.61, 95% CrI = 0.41-0.91) and OS (HR = 0.41, 95% CrI = 0.21-0.80) significantly. For patients with changes in other related DNA repair genes (but not BRCA), olaparib alone was an effective treatment. This information may assist doctors and patients in choosing the most suitable treatment based on the cancer's genetic characteristics.
    Retrospective data • Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA wild-type • BRCA mutation
    |
    Lynparza (olaparib) • abiraterone acetate
    19d
    PSMAndARPI: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=420 --> 7
    Enrollment closed • Enrollment change
    |
    Xtandi (enzalutamide) • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    19d
    InavoPC: A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open
    |
    FoundationOne® CDx
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • Itovebi (inavolisib)
    21d
    A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P3, N=750, Recruiting, Amgen | Trial primary completion date: Aug 2028 --> Jan 2030
    Trial primary completion date
    |
    docetaxel • abiraterone acetate • cabazitaxel • xaluritamig (AMG 509)
    25d
    MEVPRO-2: A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. (clinicaltrials.gov)
    P3, N=900, Recruiting, Pfizer | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial primary completion date
    |
    Xtandi (enzalutamide) • abiraterone acetate • mevrometostat (PF-06821497)